EBV

20 registered clinical trials studyying EBV — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Golidocitinib Combined With Selinexor for CAEBVD NCT07369739	Beijing Friendship Hospital	Phase 2 / Phase 3
Recruiting	Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Ad NCT06908096	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Not Yet Recruiting	KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical NCT06752473	Kousai Bio Co., Ltd.	EARLY_Phase 1
Not Yet Recruiting	A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT NCT06491719	Beijing Friendship Hospital	N/A
Unknown	Response Prediction in EBV-HLH Using Metabonomics Analysis NCT05677178	Beijing Friendship Hospital	—
Active Not Recruiting	Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults NCT04645147	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. NCT03755440	Sun Yat-sen University	Phase 2
Terminated	Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control NCT03699904	Belfast Health and Social Care Trust	Phase 2
Unknown	Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodyn NCT02878278	Huiqiang Huang	Phase 2
Completed	Comparison of Technics for Determination of Epstein-Barr Virus Serological Diagnosis NCT03650231	Centre Hospitalier Universitaire, Amiens	—
Recruiting	A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipi NCT02007356	University Hospital, Basel, Switzerland	Phase 2
Terminated	Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma NCT01948180	Cell Medica Ltd	Phase 2
Terminated	Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors NCT02080416	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	EARLY_Phase 1
Completed	Belatacept 3 Month Post Transplant Conversion Study NCT02213068	Lorenzo Gallon	Phase 4
Completed	CNTRP POSITIVE Study NCT02318030	The Hospital for Sick Children	—
Completed	Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) NCT01945814	Catherine Bollard	Phase 1
Completed	Cytotoxic T Cells to Prevent Virus Infections NCT01923766	Children's National Research Institute	Phase 1
Unknown	Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transpl NCT02779439	University of Sydney	Phase 1
Completed	Plasma EBV DNA Monitoring in Post-treatment NPC Patients NCT03973723	Taichung Veterans General Hospital	—
Recruiting	The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Know NCT01011712	National Institute of Allergy and Infectious Diseases (NIAID)	—